13F Holdings
中文EN

AIM AIM ImmunoTech Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 946644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.8%
TTM net income YoY10.3%
TTM EPS YoY93.4%
Revenue 3-yr CAGR-22.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12,800.0%
Net margin-15,526.4%
FCF margin—
EBITDA margin-11,853.8%

Returns

ROE-2,828.6%
ROA-185.4%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets27.4%
Debt / equity0.41x
Current ratio2.75x
Interest coverage-9.33x

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$88,000$170,000$202,000$141,000$135,000
R&D expense$3.92M$6.20M$10.94M$6.99M$7.67M
SG&A expense$7.70M$13.71M$21.14M$13.07M$8.67M
Operating income-$11.66M-$19.77M-$31.92M-$19.92M-$18.84M
Interest expense$812,000$585,000——$67,000
Pretax income-$13.96M————
Net income-$13.96M-$17.32M-$28.96M-$19.45M-$19.13M
EBITDA-$11.63M-$19.73M-$31.88M-$19.89M-$18.18M
EPS (basic)-8.62-30.92-0.60-0.40-0.40
EPS (diluted)-8.62-30.92-0.60-0.40-0.40
Weighted avg. shares (diluted)1.62M560,16948.59M48.05M47.34M
Balance sheet
Cash & equivalents$2.98M$1.70M$5.44M$27.05M$32.09M
Short-term investments$62,000$2.28M$7.63M$7.14M$16.18M
Receivables$7,000—$1.18M$1.68M—
Current assets$3.29M$4.18M$14.56M$36.32M$50.21M
PP&E, net$71,000$108,000$127,000$195,000$4.05M
Intangibles$1.66M$2.59M$2.31M$1.94M$1.97M
Total assets$5.78M$8.61M$19.38M$40.49M$57.70M
Current liabilities$6.22M$9.54M$8.65M$1.36M$673,000
Short-term debt$3.55M$2.31M———
Long-term debt$927,000$2.81M———
Total debt$4.48M$5.11M———
Total liabilities$15.56M$9.93M$9.15M$2.02M$820,000
Shareholders' equity-$9.78M-$1.32M$10.23M$38.47M$56.88M
Net debt$1.49M$3.41M———
Shares outstanding3.07M655,26249.10M48.08M47.99M
Cash flow statement
Operating cash flow-$10.96M-$14.89M-$21.27M-$16.11M-$13.96M
Capital expenditure—$18,000—$86,000$41,000
Free cash flow—-$14.91M—-$16.19M-$14.01M
Investing cash flow$1.85M$4.71M-$832,000$10.99M-$631,000
Financing cash flow$10.39M$6.44M$485,000$80,000$8.19M
Depreciation & amortization$37,000$37,000$39,000$38,000$659,000
Stock-based compensation$60,000$686,000$243,000$954,000$1.57M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.